ALXN

Alexion Pharmaceuticals, Inc. Press Releases

$183.24
*  
4.81
2.56%
Get ALXN Alerts
*Delayed - data as of Jan. 30, 2015  -  Find a broker to begin trading ALXN now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By
Alexion Appoints David L. Hallal as Chief Executive Officer, Effective April 1, 2015
1/29/2015 6:30:00 AM - Business Wire


Alexion Reports Fourth Quarter and Full Year 2014 Results and Provides Financial Guidance for 2015
1/29/2015 6:25:00 AM - Business Wire


Alexion Pharmaceuticals to Report Fourth Quarter and Full Year 2014 Results on Thursday, January 29, 2015
1/21/2015 10:00:00 AM - Business Wire


Alexion Pharmaceuticals to Report Fourth Quarter and Full Year 2014 Results on Thursday, January 29, 2015
1/21/2015 10:00:00 AM - Business Wire
▲1.10 % Price Change since this news event. The Volume Ratio is 0.75.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Researchers to Present New Data on Asfotase Alfa in Children with Hypophosphatasia (HPP) as well as Burden of Disease Data in Adults with HPP at ENDO 2015 Annual Meeting
1/20/2015 4:15:00 PM - Business Wire
▲0.10 % Price Change since this news event. The Volume Ratio is 0.69.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Alexion Provides Update on Phase 2 Clinical Trial with Eculizumab in Antibody Mediated Rejection (AMR) in Living-Donor Kidney Transplant Recipients
1/7/2015 4:15:00 PM - Business Wire
▼-2.50 % Price Change since this news event. The Volume Ratio is 1.79.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Alexion to Present at the J.P. Morgan 33rd Annual Healthcare Conference
1/5/2015 10:00:00 AM - Business Wire
▲0.14 % Price Change since this news event. The Volume Ratio is 2.26.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Alexion Completes Rolling BLA Submission to U.S. FDA for Asfotase Alfa as a Treatment for Patients with Hypophosphatasia
12/30/2014 6:30:00 AM - Business Wire
▼-2.90 % Price Change since this news event. The Volume Ratio is 0.64.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Alexion Announces $500 Million Share Repurchase Program
12/15/2014 6:30:00 AM - Business Wire
▼-1.96 % Price Change since this news event. The Volume Ratio is 1.59.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


X-Chem and Alexion Collaborate to Discover Novel Therapeutic Candidates to Treat Patients with Severe and Ultra-Rare Disorders
12/11/2014 8:15:00 AM - Business Wire
▼-4.28 % Price Change since this news event. The Volume Ratio is 1.15.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Soliris® (eculizumab) Granted Orphan Drug Designation in Japan for the Treatment of Patients with Myasthenia Gravis
12/10/2014 4:15:00 PM - Business Wire
▼-4.07 % Price Change since this news event. The Volume Ratio is 1.15.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


New Data Presented at ASH Annual Meeting Enhance Clinical Knowledge of aHUS and PNH and Underscore the Effectiveness of Soliris® (eculizumab) Treatment
12/8/2014 9:00:00 PM - Business Wire
▼-7.05 % Price Change since this news event. The Volume Ratio is 1.07.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


NICE Issues Final Positive Recommendation for National Commissioning of Soliris® (eculizumab) for All Patients with aHUS in England
11/27/2014 4:46:00 AM - Business Wire


Soliris® (eculizumab) Granted Orphan Drug Designation in Japan for the Treatment of Patients with Neuromyelitis Optica
11/25/2014 6:30:00 AM - Business Wire


Longer-term Outcome Data from the Largest Prospective Trial of Soliris® (eculizumab) in aHUS Underscore the Effectiveness of Ongoing Soliris Treatment
11/15/2014 10:00:00 AM - Business Wire


Alexion Announces Planned Retirement of Stephen Squinto, Ph.D., Company Co-Founder and Chief Global Operations Officer, in January 2015
11/10/2014 6:30:00 AM - Business Wire
▼-5.45 % Price Change since this news event. The Volume Ratio is 0.84.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Researchers to Present Data on Improving the Understanding of PNH and aHUS and Underscoring the Effectiveness of Soliris® (eculizumab) Treatment at ASH 2014 Annual Meeting
11/6/2014 4:15:00 PM - Business Wire
▼-5.13 % Price Change since this news event. The Volume Ratio is 0.64.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day